These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24821582)

  • 1. Carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer.
    Stewart GD; O'Mahony FC; Laird A; Rashid S; Martin SA; Eory L; Lubbock AL; Nanda J; O'Donnell M; Mackay A; Mullen P; McNeill SA; Riddick AC; Aitchison M; Berney D; Bex A; Overton IM; Harrison DJ; Powles T
    Eur Urol; 2014 Nov; 66(5):956-63. PubMed ID: 24821582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.
    Dornbusch J; Zacharis A; Meinhardt M; Erdmann K; Wolff I; Froehner M; Wirth MP; Zastrow S; Fuessel S
    PLoS One; 2013; 8(9):e76386. PubMed ID: 24086736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
    Choueiri TK; Regan MM; Rosenberg JE; Oh WK; Clement J; Amato AM; McDermott D; Cho DC; Atkins MB; Signoretti S
    BJU Int; 2010 Sep; 106(6):772-8. PubMed ID: 20230385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of serum CA9 in patients with metastatic clear cell renal cell carcinoma under targeted therapy.
    Gigante M; Li G; Ferlay C; Perol D; Blanc E; Paul S; Zhao A; Tostain J; Escudier B; Negrier S; Genin C
    Anticancer Res; 2012 Dec; 32(12):5447-51. PubMed ID: 23225450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: Grant D. Stewart, Fiach C. O'Mahony, Alexander Laird, et al. carbonic anhydrase 9 expression increases with vascular endothelial growth factor-targeted therapy and is predictive of outcome in metastatic clear cell renal cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2014.04.007.
    Kroeger N; Pantuck AJ
    Eur Urol; 2014 Oct; 66(4):e69-70. PubMed ID: 24973996
    [No Abstract]   [Full Text] [Related]  

  • 6. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.
    Motzer RJ; Hutson TE; Hudes GR; Figlin RA; Martini JF; English PA; Huang X; Valota O; Williams JA
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):739-50. PubMed ID: 25100134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
    Stubbs C; Bardoli AD; Afshar M; Pirrie S; Miscoria M; Wheeley I; Porfiri E
    Anticancer Res; 2017 Jan; 37(1):253-259. PubMed ID: 28011500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma.
    Trávníček I; Branžovský J; Kalusová K; Hes O; Holubec L; Pele KB; Ürge T; Hora M
    Anticancer Res; 2015 Oct; 35(10):5661-6. PubMed ID: 26408740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
    Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
    Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer.
    Stewart GD; Powles T; Van Neste C; Meynert A; O'Mahony F; Laird A; Deforce D; Van Nieuwerburgh F; Trooskens G; Van Criekinge W; De Meyer T; Harrison DJ
    Oncotarget; 2016 May; 7(18):25241-50. PubMed ID: 27029034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
    Ma X; Wang L; Li H; Zhang Y; Gao Y; Guo G; Liu K; Meng Q; Zhao C; Wang D; Song Z; Zhang X
    Sci Rep; 2016 Aug; 6():30886. PubMed ID: 27488093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
    de Martino M; Klatte T; Seligson DB; LaRochelle J; Shuch B; Caliliw R; Li Z; Kabbinavar FF; Pantuck AJ; Belldegrun AS
    J Urol; 2009 Aug; 182(2):728-34. PubMed ID: 19539328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer.
    Stewart GD; O'Mahony FC; Laird A; Eory L; Lubbock AL; Mackay A; Nanda J; O'Donnell M; Mullen P; McNeill SA; Riddick AC; Berney D; Bex A; Aitchison M; Overton IM; Harrison DJ; Powles T
    Clin Cancer Res; 2015 Sep; 21(18):4212-23. PubMed ID: 26015515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas.
    Paule B; Bastien L; Deslandes E; Cussenot O; Podgorniak MP; Allory Y; Naïmi B; Porcher R; de La Taille A; Menashi S; Calvo F; Mourah S
    PLoS One; 2010 May; 5(5):e10715. PubMed ID: 20502715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment.
    Tostain J; Li G; Gentil-Perret A; Gigante M
    Eur J Cancer; 2010 Dec; 46(18):3141-8. PubMed ID: 20709527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Prognostic for Survival in Japanese Patients Treated with Sunitinib as First-line Therapy for Metastatic Clear Cell Renal Cell Cancer.
    Kawai Y; Osawa T; Kobayashi K; Inoue R; Yamamoto Y; Matsumoto H; Nagao K; Hara T; Sakano S; Nagamori S; Matsuyama H
    Asian Pac J Cancer Prev; 2015; 16(14):5687-90. PubMed ID: 26320436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
    Hutson TE; Escudier B; Esteban E; Bjarnason GA; Lim HY; Pittman KB; Senico P; Niethammer A; Lu DR; Hariharan S; Motzer RJ
    J Clin Oncol; 2014 Mar; 32(8):760-7. PubMed ID: 24297950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.